A Phase 1, Double-blind, Single- and Multiple-ascending Dose Escalation Study of TNB-738, a Biparatopic Antibody Targeting CD38 in Healthy Volunteers
Latest Information Update: 22 Mar 2024
At a glance
- Drugs TNB 738 (Primary)
- Indications Fibrosis; Inflammation; Metabolic disorders
- Focus Adverse reactions; Pharmacokinetics
- Sponsors TeneoFour
- 19 Mar 2024 Status changed from recruiting to completed.
- 15 Feb 2023 Planned number of patients changed from 64 to 80.
- 15 Feb 2023 Planned End Date changed from 31 Mar 2023 to 30 Aug 2024.